Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor-mediated mTOR Inhibition in human keratinocytes

Journal of Immunology

Volumn 197, Issue 9, 2016, Pages 3545-3553

  Chiurchiù, Valerio ^a,b   Rapino, Cinzia ^c   Talamonti, Emanuela ^a,b   Leuti, Alessandro ^a,b   Lanuti, Mirko ^b   Gueniche, Audrey ^d   Jourdain, Roland ^d   Breton, Lionel ^d   Maccarrone, Mauro ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d L'ORÉAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 23; MAMMALIAN TARGET OF RAPAMYCIN; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYTOKINE; ENDOCANNABINOID; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; POLARIZATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; SKIN DISEASES;

ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; SKIN DISEASES; TH1 CELLS; TH17 CELLS; TOR SERINE-THREONINE KINASES;

EID: 84992346871     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500546     Document Type: Article

References (34)

1. Pasparakis, M., I. Haase, and F. O. Nestle. 2014. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14: 289-301.
2. Chiurchiù, V., and M. Maccarrone. 2011. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 15: 2605-2641.
3. Oddi, S., and M. Maccarrone. 2014. Phytocannabinoids and skin disorders. In Handbook of Cannabis. R. Pertwee, ed. Oxford University Press, Oxford, U.K., p. 582-600.
4. Pacher, P., and G. Kunos. 2013. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J. 280: 1918-1943.
5. Piomelli, D. 2005. The endocannabinoid system: a drug discovery perspective. Curr. Opin. Investig. Drugs 6: 672-679.
6. Maccarrone, M., E. Dainese, and S. Oddi. 2010. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem. Sci. 35: 601-608.
7. Basu, S., and B. N. Dittel. 2011. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol. Res. 51: 26-38.
8. Massa, F., G. Marsicano, H. Hermann, A. Cannich, K. Monory, B. F. Cravatt, G. L. Ferri, A. Sibaev, M. Storr, and B. Lutz. 2004. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113: 1202-1209.
9. Patsenker, E., M. Stoll, G. Millonig, A. Agaimy, T. Wissniowski, V. Schneider, S. Mueller, R. Brenneisen, H. K. Seitz, M. Ocker, and F. Stickel. 2011. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol. Med. 17: 1285-1294.
10. Kendall, A. C., and A. Nicolaou. 2013. Bioactive lipid mediators in skin inflammation and immunity. Prog. Lipid Res. 52: 141-164.
11. Pucci, M., V. Pirazzi, N. Pasquariello, and M. Maccarrone. 2011. Endocannabinoid signaling and epidermal differentiation. Eur. J. Dermatol. 21(Suppl. 2): 29-34.
12. Bíró, T., B. I. Tóth, G. Haskó, R. Paus, and P. Pacher. 2009. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol. Sci. 30: 411-420.
13. Gaffal, E., M. Cron, N. Glodde, T. Bald, R. Kuner, A. Zimmer, B. Lutz and T. Tüting. 2013. Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation. J. Immunol. 190: 4929-4936.
14. Strozyk, E., and D. Kulms. 2013. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int. J. Mol. Sci. 14: 15260-15285.
15. Buerger, C., B. Malisiewicz, A. Eiser, K. Hardt, and W. H. Boehncke. 2013. Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br. J. Dermatol. 169: 156-159.
16. Paradisi, A., N. Pasquariello, D. Barcaroli, and M. Maccarrone. 2008. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J. Biol. Chem. 283: 6005-6012.
17. Chiurchiù, V., M. T. Cencioni, E. Bisicchia, M. De Bardi, C. Gasperini, G. Borsellino, D. Centonze, L. Battistini, and M. Maccarrone. 2013. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann. Neurol. 73: 626-636.
18. Cencioni, M. T., V. Chiurchiù, G. Catanzaro, G. Borsellino, G. Bernardi, L. Battistini, and M. Maccarrone. 2010. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5: e8688.
19. Zhao, J., M. R. Benakanakere, K. B. Hosur, J. C. Galicia, M. Martin, and D. F. Kinane. 2010. Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol. Immunol. 48: 294-304.
20. Tolcher, A., J. Goldman, A. Patnaik, K. P. Papadopoulos, P. Westwood, C. S. Kelly, W. Bumgardner, L. Sams, S. Geeganage, T. Wang, et al. 2014. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. Eur. J. Cancer 50: 867-875.
21. Hausch, F., C. Kozany, M. Theodoropoulou, and A. K. Fabian. 2013. FKBPs and the Akt/mTOR pathway. Cell Cycle 12: 2366-2370.
22. Maccarrone, M., M. Di Rienzo, N. Battista, V. Gasperi, P. Guerrieri, A. Rossi, and A. Finazzi-Agrò. 2003. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J. Biol. Chem. 278: 33896-33903.
23. Sugawara, K., T. Biro, D. Tsuruta, B. I. Toth, A. Kromminga, N. Zakany, A. Zimmer, W. Funk, B. F. Gibbs, A. Zimmer, and R. Paus. 2012. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J. Allergy Clin. Immunol. 129: 726-738. e728.
24. Pucci, M., N. Pasquariello, N. Battista, M. Di Tommaso, C. Rapino, F. Fezza, M. Zuccolo, R. Jourdain, A. Finazzi Agrò, L. Breton, and M. Maccarrone. 2012. Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor. J. Biol. Chem. 287: 15466-15478.
25. Karsak, M., E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino, K. Starowicz, R. Steuder, E. Schlicker, B. Cravatt, et al. 2007. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316: 1494-1497.
26. Gaffal, E., N. Glodde, M. Jakobs, T. Bald, and T. Tüting. 2014. Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis. Exp. Dermatol. 23: 401-406.
27. Ginhoux, F., F. Tacke, V. Angeli, M. Bogunovic, M. Loubeau, X. M. Dai, E. R. Stanley, G. J. Randolph, and M. Merad. 2006. Langerhans cells arise from monocytes in vivo. Nat. Immunol. 7: 265-273.
28. Young, C. N., J. I. Koepke, L. J. Terlecky, M. S. Borkin, L. Boyd Savoy, and S. R. Terlecky. 2008. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J. Invest. Dermatol. 128: 2606-2614.
29. Mitra, A., S. K. Raychaudhuri, and S. P. Raychaudhuri. 2012. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60: 38-42.
30. Huang, T., X. Lin, X. Meng, and M. Lin. 2014. Phosphoinositide-3 kinase/ protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target? Acta Derm. Venereol. 94: 371-379.
31. Raychaudhuri, S. K., and S. P. Raychaudhuri. 2014. mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target. Indian J. Dermatol. 59: 67-70.
32. Martin, S., B. Saha, and J. L. Riley. 2012. The battle over mTOR: an emerging theatre in host-pathogen immunity. PLoS Pathog. 8: e1002894.
33. Katholnig, K., M. Linke, H. Pham, M. Hengstschläger, and T. Weichhart. 2013. Immune responses of macrophages and dendritic cells regulated by mTOR signalling. Biochem. Soc. Trans. 41: 927-933.
34. Laplante, M., and D. M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 122: 3589-3594.